About this Event
Dear Esteemed Investor,
You are exclusively invited to a Private Investor Briefing introducing Alphyn Biologics, Inc., a groundbreaking biotech company transforming the treatment of dermatological diseases.
Event Details:
📍 Fogo de Chão
201 3rd St Suite 100, San Francisco, CA
🗓 January 12, 2025 | 1 PM PST
Why Attend?
Discover why Alphyn is poised to lead the $118 billion Atopic Dermatitis (AD) market with its Zabalafin Hydrogel, a revolutionary, multi-target drug platform. After Phase 2a trials, Zabalafin has outperformed competitors, reducing investment risk while paving the way for significant near-term returns.
Key Highlights:
- De-risked Investment: Proven clinical efficacy, with Phase 2b trials ready to accelerate toward market approval.
- Massive Market Potential: A first-mover in multi-target AD treatment, addressing an unmet need in immuno-inflammatory conditions.
- Rare Exit Opportunity: Join Alphyn as they near pivotal milestones, with comparable acquisitions in the AD space delivering 20x returns in 18 months.
The Opportunity:
Alphyn is raising the final $2 million of its Series B round, following $8 million already secured. Accredited investors can join with a $500,000 minimum or $25,000 via SPV, participating at a $57 million pre-money valuation.
Attendance is limited and by invitation only. Please RSVP promptly to confirm your place and receive a calendar invitation.
RSVP Now:
To secure your spot or request additional materials (executive summary, investment deck), email Skylar Rallison at srallison@opus8.com.
Don’t miss this chance to gain insider access to one of biotech’s most promising opportunities.
We will provide a confirmation email and a calendar invitation after you register.
Your attendance will be subject to client review and availability.
Thanks much and all the best,
The Opus8 Team
Event Venue & Nearby Stays
Fogo de Chão, 201 3rd Street, San Francisco, United States
USD 0.00
